Ph I/II Ipilimumab Vemurafenib Combo
| Status: | Completed |
|---|---|
| Conditions: | Skin Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 11/18/2012 |
| Start Date: | November 2011 |
| End Date: | August 2015 |
| Contact: | For participation information at a USA site use a phone number below. For site information outside the USA please email: |
| Email: | Clinical.Trials@bms.com |
A Phase I/II Trial of Vemurafenib and Ipilimumab in Subjects With V600 BRAF Mutation-positive Metastatic Melanoma
Treatment of subjects who have metastatic melanoma that expresses an activated mutant form
of the BRAF oncogene (V600E) with a combination of the specific BRAF inhibitor, Vemurafenib,
and the Cytotoxic T Lymphocyte Antigen 4 (CTLA-4) inhibitor mAb Ipilimumab will be safe and
feasible and will show preliminary evidence of anti-tumor efficacy and survival in
comparison to historical results following treatment with either agent alone.
Inclusion Criteria:
- Metastatic melanoma with activating V600 BRAF mutation
- Measurable Tumor
- Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0-1
Exclusion Criteria:
- Autoimmune disease
- Active Brain Metastasis (must be stable after radiation for at least one month)
- Prior therapy with immune stimulating agents
We found this trial at
3
sites
University of California at Los Angeles The University of California, Los Angeles (UCLA) is an...
Click here to add this to my saved trials
Memorial Sloan-Kettering Cancer Center Memorial Sloan-Kettering Cancer Center — the world's oldest and largest private...
Click here to add this to my saved trials
Dana-Farber Cancer Institute Since it’s founding in 1947, Dana-Farber has been committed to providing adults...
Click here to add this to my saved trials